- Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
- The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
- Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
- Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets
Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico.
The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s Evergreen CBD is anticipated as the company’s product is exported this month. Mind Naturals markets to young, incoming consumers while Awe provides a customizable experience to the prestige market.
“After months of preparation, our products meet all the needs of today’s consumers and we are ready for new international markets,” Flora Beauty General Manager Andrew Restrepo stated in announcing the product orders (https://ibn.fm/IfPIP). “Incorporating cutting edge formulations, rigorous safety standards and sustainable packaging, we are confident that our products are positioned to be among the best in the beauty industry and pleased that recent industry recognition supports this.”
The announcement states Mind Naturals has garnered praise from industry marketing firms and that Spain is gaining a CBD hub reputation as a country poised to serve as the exporter for the industry’s products to surrounding countries.
Flora Growth’s Flora Lab division serves as the company’s base for research, development and manufacturing of pharmaceuticals, cosmetics and nutraceuticals with 3 GMP certifications.
Earlier this year, a major positive development in Colombia’s legal outlook on exporting dried cannabis flower and producing cannabis food and beverage products has made Flora Growths’ operational buildup pay off. Flora has now developed an international distribution pipeline for its GACP-certified flower produced at its Colombian facilities – where GACP is the precursor certification for the flower to be used to produce EU-GMP certified derivatives – that can be marketed to end users around the world.
Flora also completed an investment program in European Union GMP partner Hoshi International Inc. in August that is expected to create a pathway for European distribution of Flora’s medical cannabis products (https://ibn.fm/xVfBa).
Flora Growth President and CEO Luis Merchan will provide an update in a Dec. 14 webinar on the company’s performance for 2021 and comment on the company’s financial guidance for 2022 (https://ibn.fm/7GmNj).
For more information, visit the company’s website at www.FloraGrowth.ca.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
